Literature DB >> 23733245

Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.

Kyle M Walsh1, Terri Rice, Paul A Decker, Matthew L Kosel, Thomas Kollmeyer, Helen M Hansen, Shichun Zheng, Lucie S McCoy, Paige M Bracci, Erik Anderson, George Hsuang, Joe L Wiemels, Alexander R Pico, Ivan Smirnov, Annette M Molinaro, Tarik Tihan, Mitchell S Berger, Susan M Chang, Michael D Prados, Daniel H Lachance, Hugues Sicotte, Jeanette E Eckel-Passow, John K Wiencke, Robert B Jenkins, Margaret R Wrensch.   

Abstract

BACKGROUND: Genome-wide association studies have implicated single nucleotide polymorphisms (SNPs) in 7 genes as glioma risk factors, including 2 (TERT, RTEL1) involved in telomerase structure/function. We examined associations of these 7 established glioma risk loci with age at diagnosis among patients with glioma.
METHODS: SNP genotype data were available for 2286 Caucasian glioma patients from the University of California, San Francisco (n = 1434) and the Mayo Clinic (n = 852). Regression analyses were performed to test for associations between "number of risk alleles" and "age at diagnosis," adjusted for sex and study site and stratified by tumor grade/histology where appropriate.
RESULTS: Four SNPs were significantly associated with age at diagnosis. Carrying a greater number of risk alleles at rs55705857 (CCDC26) and at rs498872 (PHLDB1) was associated with younger age at diagnosis (P = 1.4 × 10(-22) and P = 9.5 × 10(-7), respectively). These SNPs are stronger risk factors for oligodendroglial tumors, which tend to occur in younger patients, and their association with age at diagnosis varied across tumor subtypes. In contrast, carrying more risk alleles at rs2736100 (TERT) and at rs6010620 (RTEL1) was associated with older age at diagnosis (P = 6.2 × 10(-4) and P = 2.5 × 10(-4), respectively). These SNPs are risk factors for all glioma grades/histologies, and their association with age at diagnosis was consistent across tumor subgroups.
CONCLUSIONS: Carrying a greater number of risk alleles might be expected to decrease age at diagnosis. However, glioma susceptibility conferred by variation in telomerase-related genes did not follow this pattern. This supports the hypothesis that telomerase-related mechanisms of telomere maintenance are more associated with gliomas that develop later in life than those utilizing telomerase-independent mechanisms (ie, alternative lengthening of telomeres).

Entities:  

Keywords:  age at diagnosis; glioma; single nucleotide polymorphism; telomerase; telomere

Mesh:

Substances:

Year:  2013        PMID: 23733245      PMCID: PMC3714154          DOI: 10.1093/neuonc/not051

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  30 in total

1.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

2.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

3.  A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

Authors:  Jeremy D Henson; Jonathan A Hannay; Stanley W McCarthy; Janice A Royds; Thomas R Yeager; Robert A Robinson; Stephen B Wharton; David A Jellinek; Susan M Arbuckle; Jinyoung Yoo; Bruce G Robinson; Diana L Learoyd; Paul D Stalley; S Fiona Bonar; Dihua Yu; Raphael E Pollock; Roger R Reddel
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

4.  Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication.

Authors:  Agnel Sfeir; Settapong T Kosiyatrakul; Dirk Hockemeyer; Sheila L MacRae; Jan Karlseder; Carl L Schildkraut; Titia de Lange
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

5.  Genome-wide association study identifies five susceptibility loci for glioma.

Authors:  Sanjay Shete; Fay J Hosking; Lindsay B Robertson; Sara E Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean-Yves Delattre; Khe Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu; Ching Lau; Minouk Schoemaker; Kenneth Muir; Anthony Swerdlow; Mark Lathrop; Melissa Bondy; Richard S Houlston
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Telomere length predicts replicative capacity of human fibroblasts.

Authors:  R C Allsopp; H Vaziri; C Patterson; S Goldstein; E V Younglai; A B Futcher; C W Greider; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians.

Authors:  Gil Atzmon; Miook Cho; Richard M Cawthon; Temuri Budagov; Micol Katz; Xiaoman Yang; Glenn Siegel; Aviv Bergman; Derek M Huffman; Clyde B Schechter; Woodring E Wright; Jerry W Shay; Nir Barzilai; Diddahally R Govindaraju; Yousin Suh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

9.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  28 in total

1.  Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Authors:  Quinn T Ostrom; Kathleen M Egan; L Burt Nabors; Travis Gerke; Reid C Thompson; Jeffrey J Olson; Renato LaRocca; Sajeel Chowdhary; Jeanette E Eckel-Passow; Georgina Armstrong; John K Wiencke; Jonine L Bernstein; Elizabeth B Claus; Dora Il'yasova; Christoffer Johansen; Daniel H Lachance; Rose K Lai; Ryan T Merrell; Sara H Olson; Siegal Sadetzki; Joellen M Schildkraut; Sanjay Shete; Richard S Houlston; Robert B Jenkins; Margaret R Wrensch; Beatrice Melin; Christopher I Amos; Jason T Huse; Jill S Barnholtz-Sloan; Melissa L Bondy
Journal:  Int J Cancer       Date:  2019-04-22       Impact factor: 7.396

2.  Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma.

Authors:  Victoria Zigmont; Amy Garrett; Jin Peng; Michal Seweryn; Grzegorz A Rempala; Randall Harris; Christopher Holloman; Thomas E Gundersen; Anders Ahlbom; Maria Feychting; Tom Borge Johannesen; Tom Kristian Grimsrud; Judith Schwartzbaum
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

3.  Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia.

Authors:  Kyle M Walsh; Adam J de Smith; Tara C Welch; Ivan Smirnov; Marc J Cunningham; Xiaomei Ma; Anand P Chokkalingam; Gary V Dahl; William Roberts; Lisa F Barcellos; Patricia A Buffler; Catherine Metayer; Joseph L Wiemels
Journal:  Am J Hematol       Date:  2014-04-18       Impact factor: 10.047

Review 4.  The epidemiology of glioma in adults: a "state of the science" review.

Authors:  Quinn T Ostrom; Luc Bauchet; Faith G Davis; Isabelle Deltour; James L Fisher; Chelsea Eastman Langer; Melike Pekmezci; Judith A Schwartzbaum; Michelle C Turner; Kyle M Walsh; Margaret R Wrensch; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

5.  Association between regulator of telomere elongation helicase 1 polymorphism and susceptibility to glioma.

Authors:  Shujun Pei; Feng Zhao; Junle Liu; Qiang Fu; Peizhong Shang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Authors:  Gerald F Reis; Melike Pekmezci; Helen M Hansen; Terri Rice; Roxanne E Marshall; Annette M Molinaro; Joanna J Phillips; Hannes Vogel; John K Wiencke; Margaret R Wrensch; Kyle M Walsh; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2015-05       Impact factor: 3.685

7.  POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families.

Authors:  Erica Shen; Joanne Xiu; Giselle Y Lopez; Rex Bentley; Ali Jalali; Amy B Heimberger; Matthew N Bainbridge; Melissa L Bondy; Kyle M Walsh
Journal:  J Med Genet       Date:  2020-01-14       Impact factor: 6.318

8.  The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Authors:  Robert W Rapkins; Fan Wang; HuyTram N Nguyen; Timothy F Cloughesy; Albert Lai; Wendy Ha; Anna K Nowak; Megan P Hitchins; Kerrie L McDonald
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

9.  Telomere length and risk of glioma.

Authors:  Farzana Walcott; Preetha Rajaraman; Shahinaz M Gadalla; Peter D Inskip; Mark P Purdue; Demetrius Albanes; Esther Orr; Immaculata De Vivo; Sharon A Savage
Journal:  Cancer Epidemiol       Date:  2013-11-11       Impact factor: 2.984

10.  Association between leukocyte telomere length and glioma risk: a case-control study.

Authors:  Shaolong Wang; Yibing Chen; Falin Qu; Shiming He; Xiaojun Huang; Hequn Jiang; Tianbo Jin; Shaogui Wan; Jinliang Xing
Journal:  Neuro Oncol       Date:  2013-12-22       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.